BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 33530404)

  • 1. Intestinal Chelators, Sorbants, and Gut-Derived Uremic Toxins.
    Laville SM; Massy ZA; Kamel S; Chillon JM; Choukroun G; Liabeuf S
    Toxins (Basel); 2021 Jan; 13(2):. PubMed ID: 33530404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gut microbiota; an overlooked effect of phosphate binders.
    Rahbar Saadat Y; Niknafs B; Hosseiniyan Khatibi SM; Ardalan M; Majdi H; Bahmanpoor Z; Abediazar S; Zununi Vahed S
    Eur J Pharmacol; 2020 Feb; 868():172892. PubMed ID: 31870830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of CKD on Uremic Toxins and Gut Microbiota.
    Rysz J; Franczyk B; Ławiński J; Olszewski R; Ciałkowska-Rysz A; Gluba-Brzózka A
    Toxins (Basel); 2021 Mar; 13(4):. PubMed ID: 33807343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of Gut Microbiota-Derived Uremic Toxins to the Cardiovascular System Mineralization.
    Filipska I; Winiarska A; Knysak M; Stompór T
    Toxins (Basel); 2021 Apr; 13(4):. PubMed ID: 33920096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered microbiome in chronic kidney disease: systemic effects of gut-derived uremic toxins.
    Lau WL; Savoj J; Nakata MB; Vaziri ND
    Clin Sci (Lond); 2018 Mar; 132(5):509-522. PubMed ID: 29523750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Altered Intestinal Microbiota on Chronic Kidney Disease Progression.
    Castillo-Rodriguez E; Fernandez-Prado R; Esteras R; Perez-Gomez MV; Gracia-Iguacel C; Fernandez-Fernandez B; Kanbay M; Tejedor A; Lazaro A; Ruiz-Ortega M; Gonzalez-Parra E; Sanz AB; Ortiz A; Sanchez-Niño MD
    Toxins (Basel); 2018 Jul; 10(7):. PubMed ID: 30029499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut-Derived Protein-Bound Uremic Toxins.
    Graboski AL; Redinbo MR
    Toxins (Basel); 2020 Sep; 12(9):. PubMed ID: 32932981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the gut microbial metabolic pathway with small molecules decreases uremic toxin production.
    Wang Y; Li J; Chen C; Lu J; Yu J; Xu X; Peng Y; Zhang S; Jiang S; Guo J; Duan J
    Gut Microbes; 2020 Nov; 12(1):1-19. PubMed ID: 33016221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gut Microbiome-Derived Uremic Toxin Levels in Hemodialysis Patients on Different Phosphate Binder Therapies.
    Wang LC; Tapia LM; Tao X; Chao JE; Thwin O; Zhang H; Thijssen S; Kotanko P; Grobe N
    Blood Purif; 2022; 51(8):639-648. PubMed ID: 34375976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uremic Vascular Calcification: The Pathogenic Roles and Gastrointestinal Decontamination of Uremic Toxins.
    Chao CT; Lin SH
    Toxins (Basel); 2020 Dec; 12(12):. PubMed ID: 33371477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impacts of Indoxyl Sulfate and p-Cresol Sulfate on Chronic Kidney Disease and Mitigating Effects of AST-120.
    Liu WC; Tomino Y; Lu KC
    Toxins (Basel); 2018 Sep; 10(9):. PubMed ID: 30208594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of Sevelamer on Serum Levels of Gut-Derived Uremic Toxins: Results from In Vitro Experiments and A Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
    Bennis Y; Cluet Y; Titeca-Beauport D; El Esper N; Ureña P; Bodeau S; Combe C; Dussol B; Fouque D; Choukroun G; Liabeuf S
    Toxins (Basel); 2019 May; 11(5):. PubMed ID: 31109001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of the efficacy of AST-120 (KREMEZIN
    Asai M; Kumakura S; Kikuchi M
    Ren Fail; 2019 Nov; 41(1):47-56. PubMed ID: 30732506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Uremic Toxins from the Gut Microbiota on Bone: A Brief Look at Chronic Kidney Disease.
    Black AP; Cardozo LF; Mafra D
    Ther Apher Dial; 2015 Oct; 19(5):436-40. PubMed ID: 25944654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic kidney disease and the gut microbiome.
    Hobby GP; Karaduta O; Dusio GF; Singh M; Zybailov BL; Arthur JM
    Am J Physiol Renal Physiol; 2019 Jun; 316(6):F1211-F1217. PubMed ID: 30864840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombolome and Its Emerging Role in Chronic Kidney Diseases.
    Fryc J; Naumnik B
    Toxins (Basel); 2021 Mar; 13(3):. PubMed ID: 33803899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aryl Hydrocarbon Receptor and Uremic Toxins from the Gut Microbiota in Chronic Kidney Disease Patients: Is There a Relationship between Them?
    Brito JS; Borges NA; Anjos JSD; Nakao LS; Stockler-Pinto MB; Paiva BR; Cardoso-Weide LC; Cardozo LFMF; Mafra D
    Biochemistry; 2019 Apr; 58(15):2054-2060. PubMed ID: 30912928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uremic Toxin-Producing
    Shivani S; Kao CY; Chattopadhyay A; Chen JW; Lai LC; Lin WH; Lu TP; Huang IH; Tsai MH; Teng CH; Wu JJ; Hsieh YH; Wang MC; Chuang EY
    Front Cell Infect Microbiol; 2022; 12():726256. PubMed ID: 35558102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gut-Derived Metabolites and Their Role in Immune Dysfunction in Chronic Kidney Disease.
    Glorieux G; Gryp T; Perna A
    Toxins (Basel); 2020 Apr; 12(4):. PubMed ID: 32290429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of AST-120 in Chronic Kidney Disease Treatment: Still a Controversy?
    Yamaguchi J; Tanaka T; Inagi R
    Nephron; 2017; 135(3):201-206. PubMed ID: 27960172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.